Efficacy of Hyoscine N-butyl Bromide on Cervical Dilatation Prior to Hysteroscopy Procedure: An Open-Label Randomized Controlled Trial

Background: Due to the high prevalence of intrauterine pathologies, postmenopausal women are more eligible for hysteroscopy procedure. Cervical dilatation is always a major challenge for performing hysteroscopy. The present study aimed to determine the efficacy of vaginal Hyoscine N-butylbromide (HB...

Full description

Saved in:
Bibliographic Details
Main Authors: Maryam Sadat Hosseini, Farah Farzaneh, Hanieh Najafiarab, Saba Bazzazi
Format: Article
Language:English
Published: Royan Institute (ACECR), Tehran 2025-04-01
Series:International Journal of Fertility and Sterility
Subjects:
Online Access:https://www.ijfs.ir/article_715571_798971feb103a8350e281bcbe6db105b.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Due to the high prevalence of intrauterine pathologies, postmenopausal women are more eligible for hysteroscopy procedure. Cervical dilatation is always a major challenge for performing hysteroscopy. The present study aimed to determine the efficacy of vaginal Hyoscine N-butylbromide (HBB) on cervical dilatation prior to hysteroscopy in postmenopausal women.Materials and Methods: This open-label randomized controlled trial was conducted on postmenopausal women who were scheduled for hysteroscopy. Eligible patients were randomly assigned with a ratio of 1:1 to the intervention (received 20 mg HBB vaginally two hours prior to hysteroscopy) and control (did not receive HBB) groups. As the study outcomes, pre-hysteroscopy cervical dilatation (based on the passage of the dilator No. 4 through the cervical canal) and the adverse event consequences were compared between the two groups.Results: Overall, 128 postmenopausal women who were eligible for hysteroscopy were included in the study, with 64 individuals in each group. The percentage of cervical dilatation in the intervention group was significantly higher than the control group (100% vs. 70.3%, P<0.001). Furthermore, none of the adverse event consequences differed significantly between the intervention and control groups: bleeding (3.1% vs. 3.1%, P>0.999), nausea and vomiting (4.7% vs. 0%, P=0.244), dry mouth (3.1% vs. 0%, P=0.496), dizziness (0% vs. 0%), and headache (0% vs. 0%).Conclusion: Based on the findings, vaginal HBB is an effective intervention with few side effects in cervical dilatation in postmenopausal women who are candidiates for hysteroscopy procedure.
ISSN:2008-076X
2008-0778